Durvalumab – March 2026

Solution concentrate for I.V. infusion 120 mg in 2.4 mL, Solution concentrate for I.V. infusion 500 mg in 10 mL

  • Brand names:
    • Imfinzi®
  • Pharmaceutical Company:
    • ASTRAZENECA PTY LTD
  • Condition/Indication: Gastric cancer (GC) or gastro-oesophageal junction cancer (GOJC)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026